Compare REKR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | CGEN |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.5M | 220.7M |
| IPO Year | N/A | 2000 |
| Metric | REKR | CGEN |
|---|---|---|
| Price | $1.35 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 2.5M | 591.9K |
| Earning Date | 11-13-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,028,000.00 | $6,903,000.00 |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $22.78 | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.89 | N/A |
| 52 Week Low | $0.62 | $1.13 |
| 52 Week High | $3.42 | $2.66 |
| Indicator | REKR | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 59.54 |
| Support Level | $1.33 | $2.04 |
| Resistance Level | $1.79 | $2.21 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 4.37 | 60.18 |
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.